+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
23 Aug 2017

Case Study: Dr. Reddy’s Out-Licensing deal Of DFD-06 To Encore Dermatology

Posted By

Dr. Reddy’s Laboratories Ltd., through its wholly owned subsidiary Promius Pharma, LLC announced that it has out-licensed the future development, manufacturing, and commercialization rights of DFD-06, a topical high potency steroid, to Encore Dermatology Inc. The drug is intended to be used for treatment of moderate to severe plaque psoriasis.

As per the terms of the deal, Encore will be responsible for the commercialization of DFD-06 in the United States. Promius Pharma is eligible to receive certain pre- and post- commercialization milestone payments of up to $32.5 million, followed by fixed royalty payments on net sales.

About Encore: Encore Dermatology, Inc is fully-integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.

Learn more about in and out  licensing. View

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests